RA Capital's $1.5 Million Bet: Why Insider Buying Signals a Bullish Future for Artivion

Related Articles

What's Driving RA Capital's Massive Bet on Wave Life Sciences

3 months ago

Mission Produce's Insider Bet: Why a $8.3 Million Purchase Signals a Turnaround

5 days ago

Is Apple's Recent Congressional Buying a Bullish Signal for Investors

3 months ago

Is Insider Buying a Bullish Signal for Bank of the James (BOTJ)

2 months ago

Category

You may also like

Stock News•1 week ago

Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device

Artivion (AORT) secured FDA approval for its AMDS hybrid prosthesis, removing a key hospital adoption hurdle and opening access to an estimated $150 million annual U.S. market.

AORT

Share

Stock News•1 months ago

A Robinhood Insider Just Bought a Boatload of Shares of the Beaten-Down Stock. Should Investors Follow Suit?

Robinhood director Micky Malka bought a significant number of shares in the beaten-down stock, signaling insider confidence amid the decline.

HOOD

Share

Stock News•1 months ago

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

Aurinia Pharmaceuticals CEO Kevin Tang bought 814,606 shares for ~$12.5M at $15.29 each, representing 6.66% of his prior holdings. Direct ownership remains zero post-transaction.

AUPH

Share

Stock News•1 months ago

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

Acuta Capital acquired 354,575 shares of Erasca (ERAS), a biotech firm focused on RAS/MAPK-driven oncology therapies. The investment signals institutional confidence in the company's clinical pipeline...

ERAS

Share